KH6 Stock Overview
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.60 |
| 52 Week High | US$22.80 |
| 52 Week Low | US$7.95 |
| Beta | -0.00091 |
| 11 Month Change | 11.38% |
| 3 Month Change | 25.68% |
| 1 Year Change | 116.28% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 108.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| KH6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | 0.8% | -1.3% |
| 1Y | 116.3% | -17.5% | 7.4% |
Return vs Industry: KH6 exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: KH6 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| KH6 volatility | |
|---|---|
| KH6 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: KH6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: KH6's weekly volatility has decreased from 18% to 7% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 62 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
| KH6 fundamental statistics | |
|---|---|
| Market cap | €1.79b |
| Earnings (TTM) | -€191.02m |
| Revenue (TTM) | €32.26m |
55.6x
P/S Ratio-9.4x
P/E RatioIs KH6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KH6 income statement (TTM) | |
|---|---|
| Revenue | US$33.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$33.59m |
| Other Expenses | US$232.51m |
| Earnings | -US$198.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.15 |
| Gross Margin | 100.00% |
| Net Profit Margin | -592.12% |
| Debt/Equity Ratio | 0% |
How did KH6 perform over the long term?
See historical performance and comparison